Presented at ASH: the EPCORE FL-1 study on epcoritamab in follicular lymphoma
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Unfollow podcast failed
Presented at ASH: the EPCORE FL-1 study on epcoritamab in follicular lymphoma
-
Narrated by:
-
By:
Summary
Franck Morschhauser joins Ben Abbott of The Lancet to discuss the phase 3 EPCORE FL-1 study on epcoritamab, lenalidomide, and rituximab for relapsed or refractory follicular lymphoma, which is being presented at ASH 2025.
Click here to read the full article: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02360-8/fulltext
Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv
adbl_web_anon_alc_button_suppression_c
No reviews yet